FOR INVESTORS & PARTNERS
An early-stage vision.
An evidence-led path.
NeuraBI is developing microbiome research tools for a possible future role in neurological care. The immediate priority is the pilot and the evidence needed to assess that opportunity.
In development · Recruitment openThe proposed business model
The proposed B2B2C route is through clinical partners: clinicians use the analysis and review workspace, and patients receive their approved reports. A recurring platform service is being explored. Pricing, willingness to pay, laboratory arrangements and adoption assumptions still need validation.
What we are working towards
- ↗Evaluate the prototype with clinical partners and confirm a feasible study protocol.
- ↗Establish compatible laboratory processing, independent validation and a prospective evidence base.
- ↗Test the clinical-partner business model and define the requirements for a future service.
OUR JOURNEY
Where we are,
and what comes next.
Four milestones, from the prototype that exists today to a service that would follow validation. Timing depends on research findings, partnerships and the necessary approvals.
- ✓DONE SO FAR
A working prototype
The analysis workflow, patient portal and clinician review have been implemented and tested with synthetic examples. This is software testing, not clinical validation.
- WE ARE HERE
Preparing the pilot
Agreeing the study protocol, laboratory arrangements and clinical input, and preparing for the required approvals.
- NEXT
Learn from a first study
Run the pilot once approved, with follow-up and repeat samples, to find out whether this is feasible and useful.
- LONGER TERM
Prove it before offering it
Further validation and any regulatory steps would come before a service could become available.
THE NEXT CHAPTER STARTS WITH A QUESTION.
Let’s understand
more, together.
A clinician, a researcher, a patient organisation, or simply curious? We’d like to hear from you.
Get in touch